Erlene Seymour, MD
The chronic lymphocytic leukemia (CLL) landscape has grown with a number of novel FDA-approved therapies in recent years, which has led to combination studies as well as questions surrounding how to best use these agents in practice, explained Erlene Seymour, MD.
“There are multiple combinations that are going to give us a little bit more direction on what the next step will be,” said Seymour, an oncologist at Barbara Ann Karmanos Cancer Institute, Wayne State University.
The BTK inhibitor ibrutinib (Imbruvica) has demonstrated impressive responses as a single agent, but combinations of ibrutinib with venetoclax (Venclexta), fludarabine-cyclophosphamide-rituximab (FCR), and a triplet regimen with obinutuzumab (Gazyva) and venetoclax are anticipated.
... to read the full story